Emerging functions and clinical prospects of connexins and pannexins in melanoma.
Animals
Antineoplastic Agents, Immunological
/ pharmacology
Carcinogenesis
/ drug effects
Cell Communication
/ drug effects
Cell Line, Tumor
Connexins
/ agonists
Disease Models, Animal
Disease Progression
Gap Junctions
/ drug effects
Host Microbial Interactions
/ drug effects
Humans
Melanoma
/ drug therapy
Microbiota
/ immunology
Neoplasm Invasiveness
/ immunology
Neoplasm Metastasis
/ immunology
Neoplasm Staging
Signal Transduction
/ drug effects
Skin
/ cytology
Skin Neoplasms
/ drug therapy
Tumor Microenvironment
/ drug effects
Antitumour immunity
Bystander effects
Connexin 43
Gap junctions
Hemichannels
Heterocellular communication
Melanoma
Microbiota
Pannexin 1
Tumour microenvironment
Journal
Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
29
11
2019
revised:
16
05
2020
accepted:
22
05
2020
pubmed:
29
5
2020
medline:
22
10
2020
entrez:
29
5
2020
Statut:
ppublish
Résumé
Cellular communication through gap junctions and hemichannels formed by connexins and through channels made by pannexins allows for metabolic cooperation and control of cellular activity and signalling. These channel proteins have been described to be tumour suppressors that regulate features such as cell death, proliferation and differentiation. However, they display cancer type-dependent and stage-dependent functions and may facilitate tumour progression through junctional and non-junctional pathways. The accumulated knowledge and emerging strategies to target connexins and pannexins are providing novel clinical opportunities for the treatment of cancer. Here, we provide an updated overview of the role of connexins and pannexins in malignant melanoma. We discuss how targeting of these channel proteins may be used to potentiate antitumour effects in therapeutic settings, including through improved immune-mediated tumour elimination.
Identifiants
pubmed: 32461135
pii: S0304-419X(20)30099-8
doi: 10.1016/j.bbcan.2020.188380
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Connexins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
188380Subventions
Organisme : CIHR
ID : FRN 153112
Pays : Canada
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that no conflict of interest exists. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.